Interestingly, it has been shown that cancer drug resistance, in part due to the HG-induced upregulation of hypoxic/glycolytic genes, such as HIF-1, GLUT-1, and HK-2, and to the inhibition of the JNK apoptotic pathway likely through NF-κB activation, can be counteracted by zinc(II) supplementation, which restores the drug cytotoxicity [77]. Here, HIF1A is linked to cancer.